drugset / Trial / NCT06226662

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

NCT06226662

Phase 2 Not yet recruiting 12 enrolled NovelMed Therapeutics
RandomizedSequentialDouble-blindTreatment

Summary

This is a Randomized, Double-Blind, Placebo-Controlled Study designed to assess safety, tolerability, and efficacy of NM8074 in AAV patients when used in combination with Standard of Care (SOC) cyclophosphamide/azathioprine or rituximab plus corticosteroids.

Timeline

Start
2026-06
Primary completion
2027-10
Completion
2028-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject RUXOPRUBART Monoclonal antibody 20 mg/kg Intravenous